Shandong Sinobioway Biomedicine Co., Ltd.
002581.SZ · SHZ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 3.19 | 0.90 | 0.19 | 0.01 |
| FCF Yield | -8.04% | -5.99% | -3.00% | 1.49% |
| EV / EBITDA | -203.44 | -37.90 | -41.57 | -17.30 |
| Quality | ||||
| ROIC | -1.73% | -1.91% | -2.40% | -6.28% |
| Gross Margin | 20.81% | 60.48% | 79.93% | 76.65% |
| Cash Conversion Ratio | 57.41 | 2.79 | 1.59 | – |
| Growth | ||||
| Revenue 3-Year CAGR | -15.01% | -16.50% | -3.33% | 0.31% |
| Free Cash Flow Growth | -19.75% | -89.28% | -278.57% | 3,427.83% |
| Safety | ||||
| Net Debt / EBITDA | 31.92 | 10.76 | 10.59 | 4.50 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -701.71 |
| Efficiency | ||||
| Inventory Turnover | 0.88 | 0.21 | 0.08 | 0.13 |
| Cash Conversion Cycle | 239.94 | 698.58 | 1,235.96 | 658.29 |